-
Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst
Tuesday, December 17, 2024 - 12:03pm | 292Read More...Shares of Penumbra Inc (NYSE:PEN) recovered slightly in early trading on Tuesday, after a week of correction. The Alameda, California-based company is likely to gain market share in the mechanical thrombectomy (MT) segment, according to Oppenheimer. MT is a minimally invasive procedure that removes...
-
Oppenheimer: After FDA Approval Of Tandem's Insulin Pump, Investor Focus Will Shift To 2018 Opportunities
Friday, June 22, 2018 - 3:26pm | 382Read More...Late Thursday, Tandem Diabetes Care Inc (NASDAQ: TNDM) announced FDA approval of its t:slim X2 insulin pump with Basal-IQ for Type 1 diabetes patients, which is planned for an August launch. With the company’s balance sheet position recently improved, investors will likely shift their...
-
Oppenheimer Previews Medtronic's Q4 Earnings, Remains Bullish
Wednesday, May 25, 2016 - 2:44pm | 447Read More...Oppenheimer expects Medtronic PLC (NYSE: MDT) to report "overall in-line" results when the medical device maker reports its fourth-quarter numbers on May 31. The brokerage also noted that the company's operating margin outlook is "achievable." Earnings Expectations Oppenheimer expects fourth-...
-
35 Stock Ideas Oppenheimer Analysts Love Right Now
Saturday, October 17, 2015 - 10:11pm | 1463Read More...Oppenheimer just released its 35 top stock ideas for October and November. Here’s a rundown of the full list with analyst commentary included. 1. Turtle Beach Corp (NASDAQ: HEAR) Analyst Sean McGowan sees two drivers of the stock: the “resurgence in video games” and the rollout of...
-
This Analyst Sees 25% Upside in Medtronic
Friday, September 4, 2015 - 2:30pm | 242Read More...Medtronic PLC (NYSE: MDT) is down 13 percent over the past month. Steven Lichtman at Oppenheimer reiterated the firm's Outperform rating and $86 price target. Though there are some currency headwinds, Lichtman said that the firm is eyeing double-digit EPS growth in the next couple...
-
Oppenheimer Reiterates Rating, Lowers Price Target On Insulet As New Management Begins Executing Plan
Friday, January 16, 2015 - 10:39am | 162Read More...In a report published Friday, Oppenheimer analyst Steven Lichtman reiterated an Outperform rating on Insulet Corporation (NASDAQ: PODD), but lowered the price target from $50.00 to $39.00. In the report, Oppenheimer noted, “Comments by PODD this week on '14 results indicated that US diabetes...
-
UPDATE: Oppenheimer Raises PT On Globus Medical On Pre-Announced 4Q14 Revenue
Wednesday, January 7, 2015 - 11:25am | 144Read More...In a report published Wednesday, Oppenheimer analyst Steven Lichtman reiterated an Outperform rating on Globus Medical (NYSE: GMED), and raised the price target from $24.00 to $26.00. In the report, Oppenheimer noted, “On Tuesday after the close, GMED pre-announced 4Q14 revenue of $128.5M, ahead of...
-
Oppenheimer's 5 Highlights From Medtronic's Analyst Day
Friday, June 6, 2014 - 10:59am | 379Read More...In a report published Friday, Oppenheimer analyst Steven Lichtman summarized highlights from Medtronic's (NYSE: MDT) Analyst Day. Following Medtronic's investor meeting, Lichtman emphasized the company's focus on using the changing healthcare landscape to its advantage. The analyst...
-
UPDATE: Oppenheimer Initiates Coverage on InspireMD on Novel Solution for STEMI
Tuesday, November 26, 2013 - 1:56pm | 141Read More...In a report published Tuesday, Oppenheimer analyst Steven Lichtman initiated coverage on InspireMD (NYSE: NSPR) with an Outperform rating and $6.00 price target. In the report, Oppenheimer noted, “We are initiating coverage of InspireMD, Inc. with an Outperform rating and $6 price target. We view...
-
UPDATE: Oppenheimer Initiates Sunshine Heart at Outperform on C-Pulse Potential
Thursday, July 11, 2013 - 9:05am | 147Read More...In a report published Thursday, Oppenheimer analyst Steven Lichtman initiated coverage on Sunshine Heart (NASDAQ: SSH) with an Outperform rating and $11.00 price target. In the report, Oppenheimer noted, “We are initiating coverage of SSH with an Outperform rating and $11 price target. SSH...
-
UPDATE: Oppenheimer Initiates Volcano at Outperform on Multiple Positive Factors
Thursday, July 11, 2013 - 9:04am | 147Read More...In a report published Thursday, Oppenheimer analyst Steven Lichtman initiated coverage on Volcano (NASDAQ: VOLC) with an Outperform rating and $24.00 price target. In the report, Oppenheimer noted, “We are initiating coverage of Volcano Corp. with an Outperform rating and $24 price target....
-
UPDATE: Oppenheimer Raises PT on Globus Medical Following Close of Patent Infringement Case
Monday, June 24, 2013 - 10:40am | 166Read More...In a report published Monday, Oppenheimer analyst Steven Lichtman reiterated an Outperform rating on Globus Medical (NYSE: GMED), and raised the price target from $18.00 to $19.00. In the report, Oppenheimer noted, “Now that the Synthes (JNJ) patent infringement case is behind GMED, investors...
-
Oppenheimer Reiterates Outperform Rating on Endologix Following Management Meetings
Monday, June 10, 2013 - 10:42am | 149Read More...In a report published Monday, Oppenheimer analyst Steven Lichtman reiterated an Outperform rating and $17.00 price target on Endologix (NASDAQ: ELGX). In the report, Oppenheimer noted, “ELGX shares are well off their highs owing to investor concern about the fate of Ventana. Our time with CEO...
-
UPDATE: Oppenheimer Raises PT on Medtronic Following Solid FQ4 Sales
Wednesday, May 22, 2013 - 11:28am | 174Read More...In a report published Wednesday, Oppenheimer analyst Steven Lichtman raised the price target on Medtronic (NYSE: MDT) from $52.00 to $57.00, and maintained the Outperform rating. In the report, Oppenheimer noted, “Solid F4Q sales were highlighted by improved performances from US ICD/spine....
